TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04445155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified DECIDE Parent and Provider Intervention
Description: The parent component will include up to three 60 minutes sessions. Session 1 (Decisions and Agency) is designed to increase awareness of their role in clinical interactions and encourage participation and decision making in care. Session 2 (the Who, How, and Why of Decisions) teach skills for understanding treatment decisions in terms of roles, processes, and reasons involved. Session 3 (Self-efficacy and Consolidation) encourages parents to ask questions about their adolescents' behavioral health and health care and treatment options. The provider component is designed to improve provider communication in three key areas: 1) perspective taking to understand circumstances and perceptions; 2) attributional errors or attributing negative parent behaviors to character traits; and 3) receptivity to parent participation and collaboration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified DECIDE Parent and Provider Intervention
Description: The parent component will include up to three 60 minutes sessions. Session 1 (Decisions and Agency) is designed to increase awareness of their role in clinical interactions and encourage participation and decision making in care. Session 2 (the Who, How, and Why of Decisions) teach skills for understanding treatment decisions in terms of roles, processes, and reasons involved. Session 3 (Self-efficacy and Consolidation) encourages parents to ask questions about their adolescents' behavioral health and health care and treatment options. The provider component is designed to improve provider communication in three key areas: 1) perspective taking to understand circumstances and perceptions; 2) attributional errors or attributing negative parent behaviors to character traits; and 3) receptivity to parent participation and collaboration.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Modified DECIDE Parent and Provider Intervention
Description: The parent component will include up to three 60 minutes sessions. Session 1 (Decisions and Agency) is designed to increase awareness of their role in clinical interactions and encourage participation and decision making in care. Session 2 (the Who, How, and Why of Decisions) teach skills for understanding treatment decisions in terms of roles, processes, and reasons involved. Session 3 (Self-efficacy and Consolidation) encourages parents to ask questions about their adolescents' behavioral health and health care and treatment options. The provider component is designed to improve provider communication in three key areas: 1) perspective taking to understand circumstances and perceptions; 2) attributional errors or attributing negative parent behaviors to character traits; and 3) receptivity to parent participation and collaboration.
Study: NCT03732586

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 5 fatty acid supplement
Description: Patients will be randomized to receive traditional treatment (prednisone 40 mg per day) plus omega 5 fatty acid ( 2 capsules of 0.64g per day) for 28 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Patients will be randomized to receive the traditional treatment (prednisone 40 mg per day) plus placebo (2 capsules of placebo with identical appereance and size like omega 5 supplement) for 28 days.
Study: NCT02385617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Octreotide 100mcg (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Octreotide 100mcg (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Octreotide 100mcg (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Octreotide 100mcg (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.9% saline (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% saline (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% saline (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% saline (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
Study: NCT04565756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXN407
Description: EXN407 or placebo will be administered as a single 30 microliters drop twice a day, by unilateral eye drop administration to the study eye only.
Study: NCT00870506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video
Description: 5-minute video compared (intervention) to no video and no other intervention (control)
Study: NCT03030885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-MIP-1095
Description: First Therapeutic Dose with 131I-MIP-1095 to be administered no later than 30 days after dosimetry dose, which will be designated Day 1 of the Treatment Phase 2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 41. 1st Therapeutic Dose with 131I-MIP-1095 to start after qualifying from dosimetry on Day 8 or no later than 30 days after dosimetry dose.~2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 53
Study: NCT03159845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate Oral Product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 500Mg Oral Tablet
Description: once daily from day +10 until day +30 after stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500Mg Oral Tablet
Description: once daily from day +10 until day +30 after stem cell transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole 200mg tab
Description: twice daily from day +10 until day +30 after stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole 200mg tab
Description: twice daily from day +10 until day +30 after stem cell transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir 400 MG
Description: twice daily from day +10 until day +30 after stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir 400 MG
Description: twice daily from day +10 until day +30 after stem cell transplantation
Study: NCT04424771

Intervention type: BEHAVIORAL
Intervention: Maslach Burnout Inventory (MBI)
Description: The Maslach Burnout Inventory is an introspective psychological inventory consisting of 22 items pertaining to occupational burnout.
Study: NCT00486707

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: A questionnaire will be completed.
Study: NCT04909814

Intervention type: BIOLOGICAL
Intervention: The performance of colposcopy in vaccinated women
Description: Evaluating the performance of colpscopy in HPV vaccinated women by comparing vaccinated and unvaccinated women taking their first test within the organized screening program
Study: NCT03300180

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Dementia Care Program
Description: Much of the intervention, facilitated by care coordinator, is targeted to co-manage or support the practice behavior of primary care clinicians, enhance self-management skills of both the care-recipient and the informal caregiver, and maximize the coping behavior of the patient and the informal caregiver.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening Only
Description: The patients in this group will receive screening for AD coupled with letters sent to the dyads and the primary care PCP informing them of the results of the screening
Study: NCT04315844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ewata balloon guiding
Description: The balloon guide catheter is coaxial cavity and reinforced braided catheter with varying stiffness echelon.The distal end is marked by an impermeable ray, the proximal end has a bifurcated ruhr interface, and the end is embedded with a compliance balloon.The product label indicates the size of the balloon guide catheter and the maximum volume of the balloon.
Study: NCT01797094

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A (44U)
Description: 44 units botulinum toxin Type A (total dose) per treatment. 24 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A (32U)
Description: 32 units botulinum toxin Type A (total dose) per treatment. 12 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.
Study: NCT02905643

Intervention type: OTHER
Intervention: Study subjects
Description: This study does not include an intervention it is only observational.
Study: NCT00809341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 1.4 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 100 mg/day on Days 1-5 of each cycle as part of R-CHOP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 100 mg/day on Days 1-5 of each cycle as part of R-CHOP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: 2000 mg/m\^2/day on Days 1-3 of each cycle as part of R-CHOP.
Study: NCT01438814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin placebo
Description: metformin placebo tablets 500mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linagliptin placebo
Description: linagliptin placebo tablets 5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: metformin tablets 500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: metformin tablets 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin
Description: linagliptin tablets 5mg
Study: NCT01180049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temsirolimus
Description: 175mg IV once a week for first 3 weeks, followed by 75mg IV once a week until disease progression, provided that patient is tolerating treatment and getting clinical benefit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temsirolimus
Description: 75mg IV once a week until until disease progression, provided that patient is tolerating treatment and getting clinical benefit
Study: NCT00957424

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: telephone-based intervention
Description: 10-15 minute web-based survey on a computer

Intervention type: DRUG
Group type: OTHER
Intervention: nicotine replacement therapy
Description: One week supply

Intervention type: OTHER
Group type: OTHER
Intervention: informational intervention

Intervention type: OTHER
Group type: OTHER
Intervention: internet-based intervention

Intervention type: OTHER
Group type: OTHER
Intervention: questionnaire administration
Description: Given out week 2, 3 and 4.
Study: NCT00467558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: daily
Study: NCT01935128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1 Everolimus/Reduced dose tacrolimus
Description: Immunosuppression drug intervention
Study: NCT00809341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given on Day 2 of each cycle as part of R-CHOP. Dosed according to renal function.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: 100 mg/m\^2/day on Days 1-3 of each cycle as part of R-CHOP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-dose cyclophosphamide
Description: 50 mg/kg/day on Days 2-5 of HiCy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PET scan
Description: Performed once between Days 16-20 of cycle 3 of R-CHOP.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PET scan
Description: Performed once between Days 16-20 of cycle 3 of R-CHOP.
Study: NCT04311385

Intervention type: DIAGNOSTIC_TEST
Intervention: CT imaging
Description: CT scan reported as 1-2 pericolic bubbles, but no free distant bubbles in the abdomen or abscess.
Study: NCT01681199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatin extended release tablet
Study: NCT00003597

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant human thrombopoietin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant human thrombopoietin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Study: NCT03937037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saline irrigation
Description: 100ml saline irrigation after CBD stone removal with routine ERCP procedure
Study: NCT03565692

Intervention type: BIOLOGICAL
Intervention: the lung mycobiota and microbiota profile
Description: All sputum samples will follow regarding mycological and metagenomic analyses as summarized :~* Pre-analytical treatment combining pre-treatment with mucolytic agent and sonication action~* Separation of the pellet and supernatant, stored at -20 ° C until testing~* Galactomannan (GM) Assay on each sputum supernatant to correlate with Aspergillus colonization history~* Targeted metagenomics of bacterial communities (based on 16S amplification) and of fungal community (based on ITS2 amplification)~* Bioinformatic analysis of metagenomics raw data, correlation with bioclinical data of each patient, statistical analysis, and characterization of phenomena of co-evolution/co-exclusion according to evolutionary ecology concepts.~* Pseudomonas aeruginosa load measured by qPCR

Intervention type: BIOLOGICAL
Intervention: the gut mycobiota and microbiota profile
Description: All stool samples will follow regarding mycological and metagenomic analyses as summarized : - Separation of the pellet and supernatant, stored at -20 ° C until testing - Targeted metagenomics of bacterial communities (based on 16S amplification) and of fungal community (based on ITS2 amplification) - Bioinformatic analysis of metagenomics raw data, correlation with bioclinical data of each patient, statistical analysis, and characterization of phenomena of co-evolution/co-exclusion according to evolutionary ecology concepts. - Measurement of inflammation.
Study: NCT01961674

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsinoid/placebo and rice
Description: The subject will ingest six capsinoid/placebo capsules and a standardized amount of white rice (equivalent to 50g carbohydrates). Each capsule consists 1.5mg of capsinoids, making a total dose of 9mg capsinoids.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Capsinoid/placebo and rice
Description: The subject will ingest six capsinoid/placebo capsules and a standardized amount of white rice (equivalent to 50g carbohydrates). Each capsule consists 1.5mg of capsinoids, making a total dose of 9mg capsinoids.
Study: NCT01081119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project CHOICE
Description: Voluntary after school program offered 1 day per week for 30 minutes
Study: NCT03772509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CATI
Description: The participants in this arm were read the introduction and asked for consent by a call center employee using computer-assisted telephone interviewing and then were sent a noncommunicable disease risk factor survey via interactive voice response. This mode was used to motivate participants to complete the survey.
Study: NCT03892551

Intervention type: OTHER
Intervention: Assessment of symptoms patients presenting when admitted to ED
Description: Questionnaire with a predefined list of 35 symptoms

Intervention type: OTHER
Intervention: Reason for patient presentation at ED
Description: Exploratory interview assessing reason for patient presentation at ED

Intervention type: OTHER
Intervention: physicians rating of severity of illness
Description: numeric scale ranging from 0 (perfect condition) to 10 (extremely ill)

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of vital signs
Description: Assessment of vital signs (heart rate, blood pressure, body temperature, respiration rate, peripheral capillary haemoglobin oxygen saturation)

Intervention type: OTHER
Intervention: Clinical Frailty Scale
Description: Assessment of frailty by Clinical Frailty Scale (CFS): assess patients' frailty level from 1, very fit, to 9, terminally ill

Intervention type: OTHER
Intervention: Impaired mobility on presentation (IMOP)
Description: Assessment of IMOP: defined as being unable to stand unaided or walk without help

Intervention type: OTHER
Intervention: Assessment of suspected diagnosis and differential diagnoses
Description: Assessment of treating physician's suspected diagnosis and differential diagnoses. Answers will be recorded in free text form.
Study: NCT01746277

Intervention type: DRUG
Group type: OTHER
Intervention: combined group
Description: chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycle is 6 depending on disease evaluation and patient's physical condition combined with gefitinib 250mg once per day from the start day of chemotherapy until disease progression or intolerable side effects.

Intervention type: DRUG
Group type: OTHER
Intervention: Sequenced group
Description: sequenced group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycles is 6 depending on disease evaluation or patient's physical condition sequenced by gefitinib 250mg once per day until disease progression or intolerable side effects.
Study: NCT03016949

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV
Description: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV
Description: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV
Description: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: f-IPV
Description: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: f-IPV
Description: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: f-IPV
Description: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
Study: NCT01264887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol Prolonged Release
Description: Titration to achieve sufficient pain relief to continue with effective analgesia for as long as the participant tolerates and wishes to continue treatment.
Study: NCT02447432

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (4-dose presentation)
Description: 4 doses by intramuscular injection in the right left anterolateral thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (1-dose presentation)
Description: 4 doses by intramuscular injection in the right anterolateral thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTPw-HBV/Hib
Description: 3 doses by intramuscular injection in the left anterolateral thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPw-HBV/Hib
Description: 3 doses by intramuscular injection in the left anterolateral thigh
Study: NCT00755898

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingestion of a 200 mg dose of amantadine hydrochloride
Description: Volunteer cancer patients ingest 2 x 100 mg tablets of amantadine hydrochloride with a glass of cold water 2 hours after supper.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingestion of a 200 mg dose of amantadine hydrochloride
Description: Healthy subject ingests 2 x 100 mg tablets of amantadine hydrochloride with a glass of cold water 2 hours after supper
Study: NCT00677092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: 400 mg p.o. daily for 4 months. Dosage was reduced to 200 mg if participants develop gastrointestinal intolerance or alopecia.
Study: NCT02780102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive-Motor Rehabilitation
Description: Cognitive-Motor Rehabilitation (CMR) group received 20 sixty-minute sessions of cognitive-motor exercises

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritalin
Description: 2 or 3 doses of 10 mg tablets of immediate-release Methylphenidate (Ritalin) per day for 8 week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Active Control group simultaneously received 20 sixty-minute sessions of low dose cognitive-motor exercises
Study: NCT03945162

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ruvidar® (TLD-1433) Bladder infusion and PDT
Description: Ruvidar® (TLD-1433) is infused into the bladder and treatment of bladder wall with light activation.
Study: NCT01795729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent
Description: Coronary revascularization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: optimal medical therapy
Description: Dual antiplatelet therapy: aspirin and a P2Y12 inhibitor as indicated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: optimal medical therapy
Description: Dual antiplatelet therapy: aspirin and a P2Y12 inhibitor as indicated